BioCentury
ARTICLE | Finance

Starting local, going global

Why antibody play Orum stuck with local Korean investors for its series A round

June 16, 2017 7:08 PM UTC

Orum Therapeutics Inc. plans to bring its lead antibody into the clinic with funds from local investors, but the Korean antibody company sees pharma partners and international VCs as its ticket to the global market.

Orum raised $8 million in a series A round on June 14 from Korean investors InterVest, KB Investment/Solidus Investment and LB Investment. ...

BCIQ Company Profiles

Orum Therapeutics Inc.